Andrew Haydon

机构：The Alfred Hospital, Alfred Health · ORCID：0000-0002-4631-5855

发表论文 266 篇 · 总被引 15681 次 · h-index 57

代表论文

• Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma (2024 · New England Journal of Medicine · 被引 134)
• Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial (2024 · European Journal of Cancer · 被引 85)
• Immune checkpoint inhibitor-associated myocarditis: a novel risk score (2025 · European Heart Journal · 被引 58)
• Cardiovascular disease and stroke following cancer and cancer treatment in older adults (2024 · Cancer · 被引 19)
• Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy (2024 · JAMA Surgery · 被引 19)
• Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial (2024 · The Lancet Oncology · 被引 12)